Idiopathic Early-onset Scoliosis: Growing Rods Versus Vertically Expandable Prosthetic Titanium Ribs at 5-year Follow-up.

BACKGROUND: Distraction-based techniques allow spinal growth until skeletal maturity while preventing curve progression. METHODS: Two multicenter early-onset scoliosis databases were used to identify patients with idiopathic spine abnormalities treated with traditional growing rods (TGR) or vertically expandable titanium ribs (VEPTR). Patients underwent at least 4 lengthenings and had at least 5-year follow-up. Significance was set at P<0.05. RESULTS: In total, 50 patients treated with TGR and 22 treated with VEPTR were included. Mean (±SD) age at surgery was 5.5 (±2.0) years for the TGR group versus 4.3 (±1.9) years for the VEPTR group (P=0.044); other demographic parameters were similar. VEPTR patients had more procedures (mean 15±4.2) than TGR patients (mean 10±4.0) (P=0.001). Unilateral constructs were present in 18% (4 of 22) of VEPTR and 16% (8 of 50) of TGR patients. Bilateral constructs spanned a mean 2.1 additional surgical levels and exposed patients to 1.6 fewer procedures than unilateral constructs. Curve correction was similar between bilateral and unilateral constructs. TGR patients experienced greater curve correction (50%) than VEPTR patients (27%) (P<0.001) and achieved a greater percentage of thoracic height gain (24%) than VEPTR patients (12%) (P=0.024). At latest follow-up, TGR patients had better maintenance of curve correction, less kyphosis, and 15% greater absolute gain in thoracic height versus VEPTR patients. TGR patients had a lower rate of wound complications (14%) than VEPTR patients (41%) (P=0.011). CONCLUSIONS: In patients with idiopathic early-onset scoliosis, TGRs produced greater initial curve correction, greater thoracic height gains, less kyphosis, and lower incidence of wound complications compared with VEPTR. LEVEL OF EVIDENCE: Level III.

Osteonecrosis in Sickle Cell Disease.

Osteonecrosis is one of the most devastating musculoskeletal manifestations of sickle cell disease and most commonly affects the femoral head. Although the exact pathophysiology of this condition in patients with sickle cell disease is unknown, it is suggested that red cell sickling and repetitive vaso-occlusion may be associated with tissue hypoxia, inflammation, and subsequent bone necrosis and collapse. If left untreated, osteonecrosis can be extremely debilitating and may lead to severe pain, loss of function, and degenerative joint changes. Although several conservative management approaches exist, total joint arthroplasty remains the most effective treatment intervention. A multidisciplinary approach among the primary care physician, hematologist, and orthopedic surgeon is essential in optimizing patient management.

Torsional stability of the femur after harvest of the medial femoral condyle corticocancellous flap.

BACKGROUND: Increasingly large segments of medial femoral condyle (MFC) corticocancellous flaps have been harvested for transfer. Biomechanical evaluations demonstrated no osseous stability impairment under axial loading regardless of flap size harvested. The purpose of this study was to determine the donor site's response to torsional forces. METHODS: Dual-energy X-ray absorptiometry (DEXA) scanning was performed on 16 pairs of cadaver legs followed by removal of all soft tissues, except knee capsule and ligaments. Specimens were randomly assigned to three groups with bone harvest defects measuring 3, 5, or 7 cm in length and a control group with no osseous resection. Torsional load was applied until fracture or ligamentous failure. RESULTS: Bone failure rates were 12.5, 12.5, 28.6, and 55.6% for control, 3, 5, and 7 cm groups, respectively. Bone failure rate increased with increasing harvest size; the 7 cm group demonstrated a significantly higher rate compared with the other groups combined (55.6 vs. 17.4%; p = 0.03). Failure torque was 45.5, 29.35, 27.4, and 30.83 Nm for the control, 3, 5, and 7 cm groups, respectively (p = 0.11). Harvest of any size segment resulted in a significant decrease in failure torque (p = 0.01). Bone mineral density (BMD) and Z-scores were no different among groups (p = 0.79 and 0.59, respectively). A direct relationship was identified between force required for failure and BMD (p = 0.02) and Z-scores (p = 0.05) but not for failure location and BMD (p = 0.09) or Z-scores (p = 0.94). CONCLUSION: MFC corticocancellous flap harvest of any size decreases donor site failure torque. Flap harvests > 7 cm demonstrate a higher frequency of iatrogenic fracture and therefore warrant caution with torsional loading of the knee postoperatively. Routine preoperative DEXA scans may not be warranted.

Use of reprocessed external fixators in orthopaedic surgery: a survey of 243 orthopaedic trauma surgeons.

BACKGROUND: The increasing financial burden of orthopaedic implants on our health care system has prompted cost-control measures, such as implant reprocessing. The purpose of this study was to describe the current usage by orthopaedic trauma surgeons of reprocessed external fixators (EFs) for treatment of complex fractures. METHODS: A 16-question survey about use and perceptions of reprocessed EFs was distributed to 894 Orthopaedic Trauma Association members between August 2016 and June 2017 using a web-based survey system. RESULTS: The authors received 243 responses (27%). Thirty-seven percent of respondents reported using reprocessed EFs. Nonprofit hospitals used reprocessed EFs more commonly than did for-profit hospitals (41% vs 15%, P = .0004). Eighty-seven percent of respondents believed reprocessing could be cost-effective. The most common reason (32%) for not using reprocessed EFs was coordination/logistics of reprocessing. Concern about litigation was also reported as a main reason for not using (20%) or having recently stopped using (21%) reprocessed EFs. CONCLUSIONS: Many orthopaedic traumatologists are interested in the reprocessing of EF components but few have reprocessing systems in place at their institutions. A major barrier to implementation is concern about litigation, which is likely unwarranted on the basis of Food and Drug Administration approval and a lack of previous litigation. Reprocessing by the original device manufacturers has yielded substantial savings at our institution and is an example of the cost savings that can be expected when implementing an EF reprocessing system.